153 related articles for article (PubMed ID: 10744143)
1. Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy.
Hamsten A; Syvänne M; Silveira A; Luong LA; Nieminen MS; Humphries S; Frick MH; Taskinen MR
Thromb Haemost; 2000 Mar; 83(3):397-403. PubMed ID: 10744143
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.
Grancha S; Estellés A; Tormo G; Falco C; Gilabert J; España F; Cano A; Segui R; Aznar J
Thromb Haemost; 1999 Apr; 81(4):516-21. PubMed ID: 10235431
[TBL] [Abstract][Full Text] [Related]
3. The -675 4G/5G polymorphism at the Plasminogen Activator Inhibitor 1 (PAI-1) gene modulates plasma Plasminogen Activator Inhibitor 1 concentrations in response to dietary fat consumption.
Pérez-Martínez P; Adarraga-Cansino MD; Fernández de la Puebla RA; Blanco-Molina A; Delgado-Lista J; Marín C; Ordovás JM; López-Miranda J; Pérez-Jiménez F
Br J Nutr; 2008 Apr; 99(4):699-702. PubMed ID: 17903340
[TBL] [Abstract][Full Text] [Related]
4. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
Kockx M; de Maat MP; Knipscheer HC; Kastelein JJ; Kluft C; Princen HM; Kooistra T
Thromb Haemost; 1997 Oct; 78(4):1167-72. PubMed ID: 9364979
[TBL] [Abstract][Full Text] [Related]
5. Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G/5G genotype.
Estellés A; Dalmau J; Falcó C; Berbel O; Castelló R; España F; Aznar J
Thromb Haemost; 2001 Aug; 86(2):647-52. PubMed ID: 11522017
[TBL] [Abstract][Full Text] [Related]
6. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
Lahlou-Laforet K; Alhenc-Gelas M; Pornin M; Bydlowski S; Seigneur E; Benetos A; Kierzin JM; Scarabin PY; Ducimetiere P; Aiach M; Guize L; Consoli SM
Am J Cardiol; 2006 May; 97(9):1287-91. PubMed ID: 16635597
[TBL] [Abstract][Full Text] [Related]
7. Relationship of tissue plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen with coronary artery disease in South Indian male subjects.
Deepa R; Velmurugan K; Saravanan G; Dwarakanath V; Agarwal S; Mohan V
J Assoc Physicians India; 2002 Jul; 50():901-6. PubMed ID: 12126344
[TBL] [Abstract][Full Text] [Related]
8. [Effect of physical exercise training on graft patency after aortocoronary bypass grafting].
Kubo H; Ohshima H; Hirai H; Yabuki S; Machii K; Sato K; Ebine K
J Cardiol; 1993; 23(4):319-27. PubMed ID: 8064580
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
Castelló R; España F; Vázquez C; Fuster C; Almenar SM; Aznar J; Estellés A
Thromb Res; 2006; 117(5):487-92. PubMed ID: 15907980
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of fibrinolytic factors in coronary heart disease.
Wiman B
Scand J Clin Lab Invest Suppl; 1999; 230():23-31. PubMed ID: 10389198
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly.
Mikkelsson J; Perola M; Wartiovaara U; Peltonen L; Palotie A; Penttilä A; Karhunen PJ
Thromb Haemost; 2000 Jul; 84(1):78-82. PubMed ID: 10928474
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease.
Wiman B
Thromb Haemost; 1995 Jul; 74(1):71-6. PubMed ID: 8578529
[TBL] [Abstract][Full Text] [Related]
13. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator.
Deng A; Gocke CD; Hess J; Heyman M; Paltiel M; Gaspari A
Arch Dermatol; 2006 Nov; 142(11):1466-9. PubMed ID: 17116837
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and endometriosis. Influence of PAI-1 polymorphism on PAI-1 antigen and mRNA expression.
Ramón LA; Gilabert-Estellés J; Cosín R; Gilabert J; España F; Castelló R; Chirivella M; Romeu A; Estellés A
Thromb Res; 2008; 122(6):854-60. PubMed ID: 18423526
[TBL] [Abstract][Full Text] [Related]
15. Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension.
Roncal C; Orbe J; Rodriguez JA; Belzunce M; Beloqui O; Diez J; Páramo JA
Cardiovasc Res; 2004 Jul; 63(1):176-85. PubMed ID: 15194475
[TBL] [Abstract][Full Text] [Related]
16. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction.
Huber K; Rosc D; Resch I; Schuster E; Glogar DH; Kaindl F; Binder BR
Thromb Haemost; 1988 Dec; 60(3):372-6. PubMed ID: 3149044
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels.
Kathiresan S; Gabriel SB; Yang Q; Lochner AL; Larson MG; Levy D; Tofler GH; Hirschhorn JN; O'Donnell CJ
Circulation; 2005 Sep; 112(12):1728-35. PubMed ID: 16172282
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
[TBL] [Abstract][Full Text] [Related]
19. Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting.
Walter T; Szabo S; Kazmaier S; Suselbeck T; Borggrefe M; Hoffmeister HM
Thorac Cardiovasc Surg; 2009 Sep; 57(6):368-71. PubMed ID: 19707983
[TBL] [Abstract][Full Text] [Related]
20. Association of plasminogen activator inhibitor-1 4G/5G gene polymorphism with variations in the LDL particle size in healthy Japanese men.
Kitamura Y; Okumura K; Imamura A; Mizuno T; Tsuzuki M; Numaguchi Y; Matsui H; Murohara T
Clin Chim Acta; 2004 Sep; 347(1-2):209-16. PubMed ID: 15313160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]